ANTIBODIES & BIOLOGICS 2023 LANDSCAPE REVIEWS

Antibodies and biologics drug development is a flourishing market with 12 first-time approvals in 2023, and a 79% increase in clinical trials over the last 5 years, leading to $1.156 trillion worth of deals. Enrich your understanding of antibody-based therapies with our meticulously curated analyses of the ADC, bispecific, checkpoint and cytokine landscapes. Each report offers comprehensive drug, trial and commercial insights, providing you with a panoramic view of this ever-evolving field.

Download the Landscape Reviews to access unmatched competitive intelligence, explore emerging trends and stay ahead of the curve.

Download the Reviews

Find Out More

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a Database Tailored to Your Needs